Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Topiroxostat is an inhibitor of xanthine oxidoreductase (IC50 = 5.3 nM).1 It inhibits ATP-binding cassette transporter 2 (ABCG2) in isolated human plasma (IC50 = 0.18 µM).2 Topiroxostat (5 µM) also increases LPS-induced decreases in B cell lymphoma 2 (Bcl-2) levels and decreases LPS-induced increases of Bax and cleaved caspase-3 levels in H9c2 rat cardiomyocytes.3 Chronic administration of topiroxostat results in the presence of urinary xanthine crystals and induces nephropathy in rats when administered at doses of 0.2 and 1 mg/kg, respectively.4 Formulations containing topiroxostat have been used in the treatment of gout and hyperuricemia.
WARNING This product is not for human or veterinary use.
1. Discovery of 3-
2. Identification of febuxostat as a new strong ABCG2 inhibitor: Potential applications and risks in clinical situations. Front. Pharmacol. 7(518), (2016).
3. Protective effect of topiroxostat on myocardial injury induced by lipopolysaccharide. J. Surg. Res. 271, 171-179 (2022).
4. FYX-